| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022928686 |
| P356 | DOI | 10.1186/1471-2407-14-515 |
| P932 | PMC publication ID | 4223601 |
| P698 | PubMed publication ID | 25026897 |
| P5875 | ResearchGate publication ID | 263971015 |
| P50 | author | Christos Christodoulou | Q96038899 |
| George Fountzilas | Q56432880 | ||
| Urania Dafni | Q56605609 | ||
| Christos Markopoulos | Q57033404 | ||
| P2093 | author name string | Paris Kosmidis | |
| Dimitrios Pectasides | |||
| Nicholas Pavlidis | |||
| Christos N Papandreou | |||
| Helen Gogas | |||
| Pavlos Papakostas | |||
| Constantine Dimitrakakis | |||
| Anastasia G Eleftheraki | |||
| Angelos Koutras | |||
| Dimitrios Bafaloukos | |||
| Eleni Timotheadou | |||
| Ioannis Varthalitis | |||
| Ioannis Xanthakis | |||
| Meletios-Athanassios Dimopoulos | |||
| Panagiotis Korantzopoulos | |||
| Epaminontas Samantas | |||
| Charisios Karanikiotis | |||
| Christos Papadimitriou | |||
| Spyros Miliaras | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Cancer statistics, 2010 | Q27860525 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial | Q31141377 | ||
| Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. | Q33377581 | ||
| Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial | Q57904482 | ||
| Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer | Q79782943 | ||
| Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer | Q84244064 | ||
| Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials | Q33939795 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Theoretical concepts and the emerging role of taxanes in adjuvant therapy | Q34247815 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer | Q34562115 | ||
| Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer | Q35609706 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. | Q36251476 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
| Treatment of HER2-positive breast cancer: current status and future perspectives. | Q37962332 | ||
| The adjuvant treatment of HER2-positive breast cancer | Q37992829 | ||
| Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis | Q37994471 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 | ||
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. | Q43784378 | ||
| Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials | Q45335146 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study | Q46528079 | ||
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. | Q46573303 | ||
| A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study | Q46592751 | ||
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 | ||
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an | Q57578399 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| chemotherapy | Q974135 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 515 | |
| P577 | publication date | 2014-07-15 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial | |
| P478 | volume | 14 |
| Q36908374 | Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer |
| Q92083173 | Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial |
| Q35651423 | Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA |
| Q35240718 | Gambogic Acid lysinate induces apoptosis in breast cancer mcf-7 cells by increasing reactive oxygen species |
| Q36009610 | Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer |
| Q64110303 | Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer |
| Q36754437 | Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice |
| Q37362747 | TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting |
| Q30251429 | Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. |
| Q36782680 | Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials |
| Q91779956 | lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo |
Search more.